Viking Therapeutics closes USD 292.5 million convertible senior notes offering

By Public Technologies
  • Viking Therapeutics closed a USD 258.75 million offering of 2.00% convertible senior notes due 2032.
  • Underwriters fully exercised their option for an additional USD 33.75 million of notes.
  • Gross proceeds from the notes totaled USD 292.5 million.
  • Net proceeds from the concurrent stock and note offerings were about USD 547.8 million.
  • Funds earmarked for development of VK2735, VK3019, working capital, research, development, general corporate purposes.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA58434) on September 28, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk